NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Given Consensus Rating of “Moderate Buy” by Brokerages

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) has earned an average rating of “Moderate Buy” from the five ratings firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $8.50.

NRSN has been the topic of several research reports. D. Boral Capital reissued a “buy” rating and set a $14.00 price target on shares of NeuroSense Therapeutics in a research report on Wednesday, April 8th. Weiss Ratings restated a “sell (d-)” rating on shares of NeuroSense Therapeutics in a report on Friday, May 8th. Finally, Roth Mkm began coverage on NeuroSense Therapeutics in a report on Tuesday, March 10th. They set a “buy” rating and a $3.00 price target on the stock.

Institutional Investors Weigh In On NeuroSense Therapeutics

Several large investors have recently bought and sold shares of NRSN. Yorkville Advisors Global LP purchased a new stake in NeuroSense Therapeutics during the 4th quarter worth about $77,000. Squarepoint Ops LLC increased its holdings in NeuroSense Therapeutics by 91.0% during the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after purchasing an additional 45,450 shares during the period. Jane Street Group LLC purchased a new stake in NeuroSense Therapeutics during the 2nd quarter worth about $54,000. Finally, Two Sigma Investments LP purchased a new stake in NeuroSense Therapeutics during the 3rd quarter worth about $26,000. Hedge funds and other institutional investors own 1.04% of the company’s stock.

NeuroSense Therapeutics Stock Performance

Shares of NRSN opened at $0.82 on Friday. The stock has a market capitalization of $26.70 million, a PE ratio of -1.52 and a beta of 1.60. NeuroSense Therapeutics has a 1 year low of $0.63 and a 1 year high of $2.60. The company’s 50-day simple moving average is $0.78 and its 200-day simple moving average is $0.89.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.